46
views
0
recommends
+1 Recommend
2 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Lipid regulation of the glucagon receptor family

      review-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The glucagon receptor family are typical class B1 G protein-coupled receptors (GPCRs) with important roles in metabolism, including the control of pancreas, brain, and liver function. As proteins with seven transmembrane domains, GPCRs are intimately in contact with lipid bilayers and therefore can be putatively regulated by interactions with their lipidic components, including cholesterol, sphingolipids, and other lipid species. Additionally, these receptors, as well as the agonists they bind to, can undergo lipid modifications, which can influence their binding capacity and/or elicit modified or biased signalling profiles. While the effect of lipids, and in particular cholesterol, has been widely studied for other GPCR classes, information about their role in regulating the glucagon receptor family is only beginning to emerge. Here we summarise our current knowledge on the effects of cholesterol modulation of glucagon receptor family signalling and trafficking profiles, as well as existing evidence for specific lipid–receptor binding and indirect effects of lipids via lipid modification of cognate agonists. Finally, we discuss the different methodologies that can be employed to study lipid–receptor interactions and summarise the importance of this area of investigation to increase our understanding of the biology of this family of metabolically relevant receptors.

          Related collections

          Most cited references157

          • Record: found
          • Abstract: not found
          • Article: not found

          Understanding the diversity of membrane lipid composition

            • Record: found
            • Abstract: found
            • Article: not found

            High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

            Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors constitute the largest family of eukaryotic signal transduction proteins that communicate across the membrane. We report the crystal structure of a human beta2-adrenergic receptor-T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom resolution. The structure provides a high-resolution view of a human G protein-coupled receptor bound to a diffusible ligand. Ligand-binding site accessibility is enabled by the second extracellular loop, which is held out of the binding cavity by a pair of closely spaced disulfide bridges and a short helical segment within the loop. Cholesterol, a necessary component for crystallization, mediates an intriguing parallel association of receptor molecules in the crystal lattice. Although the location of carazolol in the beta2-adrenergic receptor is very similar to that of retinal in rhodopsin, structural differences in the ligand-binding site and other regions highlight the challenges in using rhodopsin as a template model for this large receptor family.
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Glucagon-like peptide 1 (GLP-1)

              Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. Scope of review In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. Major conclusions Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders

                Author and article information

                Journal
                J Endocrinol
                J Endocrinol
                JOE
                The Journal of Endocrinology
                Bioscientifica Ltd (Bristol )
                0022-0795
                1479-6805
                06 May 2024
                10 April 2024
                01 June 2024
                : 261
                : 3
                : e230335
                Affiliations
                [1 ]Section of Cell Biology and Functional Genomics , Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
                [2 ]Department of Surgery and Cancer , Imperial College London, London, UK
                [3 ]Section of Investigative Medicine , Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
                [4 ]Department of Life Sciences , Imperial College, London, UK
                Author notes
                Correspondence should be addressed to A Tomas: a.tomas-catala@ 123456imperial.ac.uk

                This paper forms part of a special collection on Incretins. The guest editors for this collection were Timo D Müller and Erin Mulvihill.

                Author information
                http://orcid.org/0000-0002-0968-6972
                http://orcid.org/0000-0002-2290-8453
                Article
                JOE-23-0335
                10.1530/JOE-23-0335
                11103681
                38614123
                6171c57b-69f9-42a8-801b-0dc2dcaad253
                © the author(s)

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : 30 October 2023
                : 09 April 2024
                Funding
                Funded by: Diabetes UK, doi http://dx.doi.org/10.13039/501100000361;
                Funded by: Boehringer Ingelheim, doi http://dx.doi.org/10.13039/100001003;
                Funded by: Academy of Medical Sciences, doi http://dx.doi.org/10.13039/501100000691;
                Funded by: Wellcome Trust, doi http://dx.doi.org/10.13039/100010269;
                Categories
                Thematic Review

                Endocrinology & Diabetes
                lipid,glucagon receptor,glp-1 receptor,gip receptor,cholesterol
                Endocrinology & Diabetes
                lipid, glucagon receptor, glp-1 receptor, gip receptor, cholesterol

                Comments

                Comment on this article

                Related Documents Log